尿液肿瘤DNA分层接受阿替利珠单抗治疗的BCG无应答NMIBC复发风险
本研究分析SWOG S1605试验中接受阿替利珠单抗治疗的BCG无应答非肌层浸润性膀胱癌患者的尿液肿瘤DNA(utDNA),使用UroAmp检测基线(89例)和3个月(77例)样本。基线UroAmp阳性患者6个月完全缓解率仅13%,阴性为71%(p<0.001);基线阳性者18个月无事件生存率23%,阴性51%(HR 2.8,p<0.001)。3个月无临床证据疾病患者中,阳性者18个月EFS为38%,阴性86%(HR 3.5,p=0.01)。
要点
- 基线utDNA阳性与阿替利珠单抗治疗完全缓解率低及EFS差显著相关。
- 治疗3个月时utDNA阳性可识别无临床疾病但高复发风险患者。
- utDNA动态监测有助于指导BCG无应答NMIBC的治疗决策。
核心结论
- 基线及治疗3个月时utDNA检测可识别BCG无应答NMIBC中从系统性免疫治疗获益可能性低的患者。
研究设计与样本
- 分析SWOG S1605试验中接受阿替利珠单抗治疗的BCG无应答NMIBC患者尿液样本,基线89例、3个月77例,使用UroAmp检测utDNA。
主要发现
- 基线UroAmp阳性患者6个月完全缓解率为13%,阴性患者为71%(p<0.001)。
- 基线UroAmp阳性患者18个月EFS为23%,阴性为51%(HR 2.8,p<0.001)。
- 3个月无临床证据疾病患者中(n=51),UroAmp阳性18个月EFS为38%,阴性为86%(HR 3.5,p=0.01)。
临床怎么用
- 可考虑在基线及治疗3个月时采用utDNA检测对BCG无应答NMIBC患者进行风险分层,辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As new treatments for bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) emerge, better methods are needed to guide therapeutic decisions. This study analyzed urine tumor DNA (utDNA) from patients treated with atezolizumab in the SWOG S1605 trial to determine whether utDNA profiling can stratify the risk of treatment failure. Urine samples were analyzed using the UroAmp assay at baseline and 3 mo from 89 and 77 patients, respectively. Only 13% of UroAmp-positive patients at baseline achieved a complete response at 6 mo compared with 71% of UroAmp-negative patients (p < 0.001). The 18-mo event-free survival (EFS) was significantly lower for UroAmp-positive patients at baseline (23%) than for UroAmp-negative patients (51%; hazard ratio [HR] 2.8, p < 0.001). Among patients with no clinical evidence of disease at 3 mo (n = 51), the 18-mo EFS was 38% for UroAmp-positive and 86% for UroAmp-negative (HR 3.5, p = 0.01) patients. These findings suggest that utDNA profiling at baseline and after 3 mo of treatment can help identify patients with BCG-unresponsive NMIBC who are less likely to benefit from systemic immunotherapy.
引用
- St-Laurent MP, Singh P, McConkey DJ, et al. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol. 2025. PMID: 40404526. doi:10.1016/j.eururo.2025.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。